U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07177235) titled 'Ketamine for the Treatment of Refractory Status Epilepticus' on Sept. 03.
Brief Summary: This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Refractory Status Epilepticus
Intervention:
DRUG: Ketamine
Timing of ketamine initiation will differ between groups (early versus late ketamine)
DRUG: Midazolam
Midazolam infusion will be initiated at the same time in both groups
Recruitment Status: NOT_YE...